BeyondSpring is a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer therapies. Its lead asset, Plinabulin, is a first-in-class drug candidate that treats non-small cell lung cancer and prevents chemotherapy-induced neutropenia.
Authors
Dr. Lan Huang
Co-founder, Chairman and CEO of BeyondSpringDr. Lan Huang is Co-founder, Chairman and CEO of BeyondSpring. Dr. Huang has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry and invented and holds pate...
